DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Atorvastatin Calcium in Preventing Metabolic Syndrome in Patients With Prostate Cancer Receiving Long-Term Androgen-Deprivation Therapy

Information source: University of Nebraska
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer

Intervention: atorvastatin calcium (Drug); placebo (Drug)

Phase: N/A

Status: Withdrawn

Sponsored by: University of Nebraska

Official(s) and/or principal investigator(s):
Jue Wang, Principal Investigator, Affiliation: University of Nebraska

Summary

This randomized pilot clinical trial studies atorvastatin calcium in preventing metabolic syndrome in patients with prostate cancer receiving long-term androgen-deprivation therapy. Atorvastatin calcium may help prevent or reduce metabolic syndrome caused by long-term androgen-deprivation therapy

Clinical Details

Official title: A Pilot Study of Atorvastatin on Prevention of Metabolic Syndrome in Subjects With Prostate Cancer on Long Term Androgen-deprivation Therapy

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome:

Overall change of metabolic syndrome score (divided into 6 groups according to the number of constituents [0-5] of metabolic syndrome)

Change in effectiveness of atorvastatin calcium on the prevention of metabolic syndrome

Secondary outcome:

Change in Safety and tolerability of atorvastatin calcium

Impact of atorvastatin calcium on mean change in PSA and PSA velocity

Optional collection and banking of blood and serum on subjects for future analysis

Detailed description: PRIMARY OBJECTIVES: I. To evaluate in a pilot study a preliminary estimate of the overall change of metabolic syndrome score in men undergoing or who have undergone androgen-deprivation therapy for treatment or the control of prostate cancer. II. To assess the effectiveness of Atorvastatin (atorvastatin calcium) on the prevention of metabolic syndrome in men undergoing or who have undergone androgen-deprivation therapy for treatment or the control of prostate cancer. SECONDARY OBJECTIVES: I. To document the safety and tolerability of Atorvastatin in this patient population. II. To assess the impact of Atorvastatin on mean change in prostate specific antigen (PSA) and PSA velocity. III. The collection and banking of blood and serum on subjects for future analysis that will be proposed in future institutional review board (IRB) submissions. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive placebo orally once daily for 6 months in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive atorvastatin calcium orally once daily for 6 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, and at 6 months thereafter.

Eligibility

Minimum age: 19 Years. Maximum age: N/A. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Histologically confirmed prostate cancer, any stage disease allowed Androgen

deprivation for treatment or control of prostate cancer including any of the following:

- Bilateral orchiectomy

- Luteinizing hormone-releasing hormone (LHRH) agonist therapy (e. g., leuprolide,

goserelin, bicalutamide, flutamide, or similar agents) with or without antiandrogen therapy

- No statin therapy, antihyperlipidemic, lipid-lowering medications, HMG-COA reductase

inhibitor, atorvastatin calcium, or LIPITOR ® use

- Patients must be willing to give written informed consent, and sign an

institutionally approved consent form before performance of any study-related procedure not part of normal medical care based on current diagnosis and clinical condition, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care

- Karnofsky Performance Status >= 70

- Able to adhere to the study visit schedule and other protocol requirements

- No serious disease or condition that, in the opinion of the investigator, would

compromise the patient's ability to participate in the study

- Absolute neutrophil count (ANC) >= 1000 cells/mm^3

- Platelet Count >= 100 mm^3

- Serum creatinine < 2. 0 mg/dL

- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2 x the upper

limits of normal

- Hepatic alkaline phosphatase < 2 x the upper limits of normal

Exclusion Criteria:

- Treatment with a cytotoxic chemotherapy or participation in any other studies

involving investigational or marketed products, concomitantly within 30 days before Day 1 of study treatment; palliative radiation therapy is allowed

- Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type

A, B or C or active Hepatitis

- Known alcohol and/or any other drug abuse

- History of intolerance or hypersensitivity to statins and known hypersensitivity to

atorvastatin

- Known history of non-low-density lipoprotein (LDL) cholesterol > 150 mg/dL,

peripheral artery disease, coronary heart disease, myocardial infarction (MI) or angina, coronary artery disease or diabetes (as should be receiving statin therapy per current standards); in addition, patients with a known history of smoking, hypertension, family history of myocardial events, and non-LDL > 100 mg/dL

- Any evidence of severe or uncontrolled systemic disease (e. g., unstable or

uncompensated respiratory, cardiac, hepatic, or renal disease) as assessed by the investigator

- Known cerebrovascular accidents within 6 months before Day 1 of study treatment

- Treatment with drugs not permitted by the study protocol or the likelihood of

requiring treatment during the study period with drugs which might interfere with the absorption and evaluation of study drugs during the study protocol

- Any other clinically significant medical disease or condition laboratory abnormality

or psychiatric illness that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent

Locations and Contacts

Additional Information

Starting date: March 2012
Last updated: June 17, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017